These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

199 related articles for article (PubMed ID: 22167612)

  • 41. Rituximab with or without a conventional maintenance agent in the treatment of relapsing granulomatosis with polyangiitis (Wegener's): a retrospective single-center study.
    Azar L; Springer J; Langford CA; Hoffman GS
    Arthritis Rheumatol; 2014 Oct; 66(10):2862-70. PubMed ID: 24943239
    [TBL] [Abstract][Full Text] [Related]  

  • 42. Efficacy of mycophenolate mofetil in patients with diffuse proliferative lupus nephritis. Hong Kong-Guangzhou Nephrology Study Group.
    Chan TM; Li FK; Tang CS; Wong RW; Fang GX; Ji YL; Lau CS; Wong AK; Tong MK; Chan KW; Lai KN
    N Engl J Med; 2000 Oct; 343(16):1156-62. PubMed ID: 11036121
    [TBL] [Abstract][Full Text] [Related]  

  • 43. Efficacy and safety of rituximab treatment in children with primary glomerulonephritis.
    Zachwieja J; Silska M; Ostalska-Nowicka D; Soltysiak J; Lipkowska K; Blumczynski A; Musielak A
    J Nephrol; 2012; 25(6):1060-6. PubMed ID: 22322817
    [TBL] [Abstract][Full Text] [Related]  

  • 44. B-cell depleting agents for ANCA vasculitides: a new therapeutic approach.
    Gómez-Puerta JA; Quintana LF; Stone JH; Ramos-Casals M; Bosch X
    Autoimmun Rev; 2012 Jul; 11(9):646-52. PubMed ID: 22146313
    [TBL] [Abstract][Full Text] [Related]  

  • 45. Late acute antibody mediated rejection after nine years of renal transplantation.
    Halim MA; Al-Otaibi T; Al-Waheeb S; Tawab KA; El Kholy O; Nair P; Said T; Narayanan Nampoory MR
    Saudi J Kidney Dis Transpl; 2010 Nov; 21(6):1111-4. PubMed ID: 21060182
    [TBL] [Abstract][Full Text] [Related]  

  • 46. [Immunosuppressive treatment].
    Niaudet P
    Nephrol Ther; 2011 Dec; 7(7):592-8. PubMed ID: 22118788
    [TBL] [Abstract][Full Text] [Related]  

  • 47. [Immunosuppressive treatments: mechanisms of action and clinical use].
    Thervet E; Zuber J; Sberro R; Canaud G; Anglicheau D; Snanoudj R; Mamzer-Bruneel MF; Martinez F; Legendre C
    Nephrol Ther; 2011 Dec; 7(7):566-81. PubMed ID: 21273149
    [TBL] [Abstract][Full Text] [Related]  

  • 48. Clinical assessment and management of cytopenias in lupus patients.
    Levine AB; Erkan D
    Curr Rheumatol Rep; 2011 Aug; 13(4):291-9. PubMed ID: 21503695
    [TBL] [Abstract][Full Text] [Related]  

  • 49. Rituximab and lupus interstitial lung disease: friend or foe?
    Efthimiou P; Kukar M; Hersh A
    Int J Rheum Dis; 2011 Feb; 14(1):e3-4. PubMed ID: 21303472
    [No Abstract]   [Full Text] [Related]  

  • 50. Research and therapeutics-traditional and emerging therapies in systemic lupus erythematosus.
    Davis LS; Reimold AM
    Rheumatology (Oxford); 2017 Apr; 56(suppl_1):i100-i113. PubMed ID: 28375452
    [TBL] [Abstract][Full Text] [Related]  

  • 51. Rituximab versus azathioprine for maintenance in ANCA-associated vasculitis.
    Guillevin L; Pagnoux C; Karras A; Khouatra C; Aumaître O; Cohen P; Maurier F; Decaux O; Ninet J; Gobert P; Quémeneur T; Blanchard-Delaunay C; Godmer P; Puéchal X; Carron PL; Hatron PY; Limal N; Hamidou M; Ducret M; Daugas E; Papo T; Bonnotte B; Mahr A; Ravaud P; Mouthon L;
    N Engl J Med; 2014 Nov; 371(19):1771-80. PubMed ID: 25372085
    [TBL] [Abstract][Full Text] [Related]  

  • 52. Induction therapy for active lupus nephritis: mycophenolate mofetil versus cyclophosphamide.
    Burchardi C; Schlöndorff D
    Nat Clin Pract Nephrol; 2006 Jun; 2(6):314-5. PubMed ID: 16932452
    [No Abstract]   [Full Text] [Related]  

  • 53. [Role of monoclonal antibodies in the treatment of immune-mediated kidney disease: the state of the art].
    Cravedi P
    G Ital Nefrol; 2012; 29(3):274-82; discussion 292. PubMed ID: 22718450
    [TBL] [Abstract][Full Text] [Related]  

  • 54. Treatment of lupus nephritis--a work in progress.
    Falk RJ
    N Engl J Med; 2000 Oct; 343(16):1182-3. PubMed ID: 11036127
    [No Abstract]   [Full Text] [Related]  

  • 55. A comparison of oral methylprednisolone plus azathioprine or mycophenolate mofetil for the treatment of bullous pemphigoid.
    Beissert S; Werfel T; Frieling U; Böhm M; Sticherling M; Stadler R; Zillikens D; Rzany B; Hunzelmann N; Meurer M; Gollnick H; Ruzicka T; Pillekamp H; Junghans V; Bonsmann G; Luger TA
    Arch Dermatol; 2007 Dec; 143(12):1536-42. PubMed ID: 18087004
    [TBL] [Abstract][Full Text] [Related]  

  • 56. Efficacy and safety of rituximab in patients with active proliferative lupus nephritis: the Lupus Nephritis Assessment with Rituximab study.
    Rovin BH; Furie R; Latinis K; Looney RJ; Fervenza FC; Sanchez-Guerrero J; Maciuca R; Zhang D; Garg JP; Brunetta P; Appel G;
    Arthritis Rheum; 2012 Apr; 64(4):1215-26. PubMed ID: 22231479
    [TBL] [Abstract][Full Text] [Related]  

  • 57. [Treatment of proliferative glomerulonephritis of systemic lupus erythematosus. Recent development and current recommendations].
    Daugas E
    Rev Med Interne; 2008 Sep; 29(9):710-7. PubMed ID: 18565625
    [TBL] [Abstract][Full Text] [Related]  

  • 58. Update on the pharmacological treatment of adult myositis.
    Oddis CV
    J Intern Med; 2016 Jul; 280(1):63-74. PubMed ID: 27098592
    [TBL] [Abstract][Full Text] [Related]  

  • 59. Rituximab in the treatment of anti-neutrophil cytoplasm antibody-associated vasculitis.
    Jones RB
    Nephron Clin Pract; 2014; 128(3-4):243-9. PubMed ID: 25401382
    [TBL] [Abstract][Full Text] [Related]  

  • 60. Current therapy of the pemphigus group.
    Kasperkiewicz M; Schmidt E; Zillikens D
    Clin Dermatol; 2012; 30(1):84-94. PubMed ID: 22137231
    [TBL] [Abstract][Full Text] [Related]  

    [Previous]   [Next]    [New Search]
    of 10.